11 September 2020 - NICE has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding.

However, treatment with the drug within the NHS will only be funded if the bleed is in the gastrointestinal tract and the company provides the drug as per the terms of agreed commercial arrangement.

Ondexxya is recommended by NICE only in research for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull.

Read Pharma Times article